Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome

被引：1
|
作者：
Toh, Han Chong
Yong, Wei Peng
Wang, Yu-Ning
Tan, Eng-Huat
Kollmannsberger, Christian K.
Devanarayan, Viswanath
Zhang, Ke
Luo, Yanping
Chen, Daniel
Ashton, Edward
Ricker, Justin L.
Carlson, Dawn
Chen, Pei-Jer
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-A105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A105
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
    Janette Vardy
    Ryan Dadasovich
    Philip Beale
    Michael Boyer
    Stephen J Clarke
    BMC Cancer, 9
  • [22] Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib
    Kelly, Ronan J.
    Rajan, Arun
    Force, Jeremy
    Lopez-Chavez, Ariel
    Keen, Corrine
    Cao, Liang
    Yu, Yunkai
    Choyke, Peter
    Turkbey, Baris
    Raffeld, Mark
    Xi, Liqiang
    Steinberg, Seth M.
    Wright, John J.
    Kummar, Shivaani
    Gutierrez, Martin
    Giaccone, Giuseppe
    CLINICAL CANCER RESEARCH, 2011, 17 (05) : 1190 - 1199
  • [23] Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic, D.
    Golubicic, I.
    Gavrilovic, D.
    Kezic, I.
    Jelic, S.
    JOURNAL OF BUON, 2009, 14 (02): : 203 - 209
  • [24] Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic, Davorin Z.
    Golubicic, Ivana
    Gavrilovic, Dusica
    Kezic, Iva
    Jelic, Svetislav
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S540 - S541
  • [25] THE OUTCOME OF THE ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT USING STANDARD DOUBLETS OUTSIDE OF CLINICAL TRIALS
    Chmielowska, Ewa
    Kwiatkowski, Mariusz
    Studzinski, Maciej
    Chabowski, Ryszard
    Kalinowska, Katarzyna
    Kopec, Jan
    Krauze, Anna
    Lewandowska, Kinga
    Olejniczak, Moinka
    Swiezynski, Marcin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1267 - S1268
  • [26] EFFICACY OF PET-CT IN EVALUATION OF RESPONSE IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
    Roy, S.
    Pathy, S.
    Kumar, R.
    Mohanti, B. K.
    Raina, V.
    Jaiswal, A.
    Malhotra, A.
    Thulkar, S.
    Mohan, A.
    Mathur, S.
    Behera, D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [27] Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)
    Fanucchi, M
    Fossella, F
    Fidias, P
    Natale, R
    Belt, R
    Govindan, R
    Raez, L
    Schiller, J
    Kashala, O
    Kelly, K
    LUNG CANCER, 2005, 49 : S30 - S30
  • [28] Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
    Besse, Benjamin
    Planchard, David
    Veillard, Anne-Sophie
    Taillade, Laurent
    Khayat, David
    Ducourtieux, Muriel
    Pignon, Jean-Pierre
    Lumbroso, Jean
    Lafontaine, Carole
    Mathiot, Claire
    Soria, Jean-Charles
    LUNG CANCER, 2012, 76 (01) : 78 - 83
  • [29] ASSESSMENT OF QUALITY OF LIFE (QOL) IN PHASE III TRIALS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Adamowicz, K.
    Saad, E. D.
    Katz, A.
    Jassem, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 147 - 147
  • [30] Gemcitabine in the treatment of advanced non-small cell lung cancer: review of main phase II and III trials
    Crino, L
    Cappuzzo, F
    ANTI-CANCER DRUGS, 2001, 12 : S9 - S13
12345